Cargando…

Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease

Background: The EXCEED study evaluated the efficacy and safety of secukinumab versus adalimumab in psoriatic arthritis, but it did not include a pharmacoeconomic analysis. The objective of this study was to compare the cost per responder of secukinumab versus adalimumab in patients with psoriatic di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gisondi, Paolo, Geat, Davide, Maurelli, Martina, Degli Esposti, Luca, Bellinato, Francesco, Girolomoni, Giampiero
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142895/ https://www.ncbi.nlm.nih.gov/pubmed/35632402 http://dx.doi.org/10.3390/vaccines10050646

Ejemplares similares

Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2022)

Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis
por: Bellinato, Francesco, et al.
Publicado: (2022)

Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy
por: Gisondi, Paolo, et al.
Publicado: (2014)

Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines
por: Bellinato, Francesco, et al.
Publicado: (2021)

Alopecic and aseptic nodules of the scalp: A new case with a systematic review of the literature
por: Bellinato, Francesco, et al.
Publicado: (2021)

Psychological Stress and Salivary Cortisol Levels in Patients with Plaque Psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2021)

Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis
por: Maurelli, Martina, et al.
Publicado: (2023)

Increased red blood cell distribution width in patients with plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2021)

Recurrent cutaneous eosinophilic vasculitis characterized by annular purpuric lesions: A case report
por: Gisondi, Paolo, et al.
Publicado: (2023)

Advanced Glycation End Products and Psoriasis
por: Maurelli, Martina, et al.
Publicado: (2023)

Topographic Differential Diagnosis of Chronic Plaque Psoriasis: Challenges and Tricks
por: Gisondi, Paolo, et al.
Publicado: (2020)

Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules
por: Bellinato, Francesco, et al.
Publicado: (2021)

Clinical Characteristics of Patients with Pustular Psoriasis: A Single-Center Retrospective Observational Study
por: Gisondi, Paolo, et al.
Publicado: (2022)

Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review
por: Dal Bello, Giacomo, et al.
Publicado: (2020)

Annually Recurring Erythema Annulare Centrifugum: A New Case Series with Review of the Literature
por: Maurelli, Martina, et al.
Publicado: (2021)

Uncommon Non-Infectious Annular Dermatoses
por: Maurelli, Martina, et al.
Publicado: (2022)

Amicrobial Pustulosis of the Folds: Report of Three New Cases
por: Bellinato, Francesco, et al.
Publicado: (2020)

Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities
por: Gisondi, Paolo, et al.
Publicado: (2020)

Immune Response to Vaccination in Patients with Psoriasis Treated with Systemic Therapies
por: Chiricozzi, Andrea, et al.
Publicado: (2020)

The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments
por: Gisondi, Paolo, et al.
Publicado: (2020)

Cutaneous Adverse Reactions to SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis
por: Bellinato, Francesco, et al.
Publicado: (2022)

Central Pain Sensitization in Patients with Chronic Plaque Psoriasis
por: Bellinato, Francesco, et al.
Publicado: (2023)

Costo per responder di risankizumab e secukinumab nel trattamento della psoriasi a placche da moderata a grave in Italia
por: Gisondi, Paolo, et al.
Publicado: (2021)

Advanced Glycation End Products in the Pathogenesis of Psoriasis
por: Papagrigoraki, Anastasia, et al.
Publicado: (2017)

Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies
por: Esposti, Luca Degli, et al.
Publicado: (2018)

Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
por: Strand, Vibeke, et al.
Publicado: (2017)

Pruritus as a Distinctive Feature of Type 2 Inflammation
por: Garcovich, Simone, et al.
Publicado: (2021)

A Cost per Responder Model for Abatacept versus Adalimumab Among Rheumatoid Arthritis Patients with Seropositivity
por: Park, Sang Hee, et al.
Publicado: (2020)

Psoriatic Arthritis That Responded Dramatically When Infliximab Was Switched to Adalimumab
por: Ohshima, Yuichiro, et al.
Publicado: (2013)

Association between short-term exposure to environmental air pollution and atopic dermatitis flare in patients treated with dupilumab
por: Bellinato, Francesco, et al.
Publicado: (2023)

Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
por: Buchanan, Vanessa, et al.
Publicado: (2018)

Secukinumab in Ankylosing Spondylitis Patients: A Cost-per-Responder Analysis from the Indonesian Health System Perspective
por: Wahono, Cesarius Singgih, et al.
Publicado: (2023)

Glomerular filtration rate in patients with psoriasis treated with etanercept
por: Gisondi, Paolo, et al.
Publicado: (2016)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016)

Secukinumab for ankylosing spondylitis and psoriatic arthritis
por: Lubrano, Ennio, et al.
Publicado: (2016)

Secukinumab: A Review in Psoriatic Arthritis
por: Blair, Hannah A.
Publicado: (2021)

A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy
por: Cortesi, Paolo Angelo, et al.
Publicado: (2023)

Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Management of Moderate to Severe Psoriasis in Patients with Metabolic Comorbidities
por: Gisondi, Paolo, et al.
Publicado: (2015)

A Review of the Use of Secukinumab for Psoriatic Arthritis
por: Patel, Nupur U., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_o8u3i8pjurdnminb4uhhqjl7pr